Novarel Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Novarel market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to several factors, including the rising adoption of IVF, expanded government fertility programs, improvements in fertility clinics, greater social acceptance of fertility treatments, and a growing focus on personalized medicine.

The growth anticipated during the forecast period can be attributed to factors such as the rise in fertility tourism, advancements in healthcare infrastructure, initiatives from both the government and private sector, research into alternatives to fertility drugs, and environmental factors affecting reproductive health. Key trends expected during this period include a shift toward biosimilars, the emergence of personalized fertility treatments, increased availability of fertility services, a focus on chronic disease management, and sustainability initiatives.

The growth of the novarel market is being driven by the increasing prevalence of infertility. Infertility is defined as the inability to conceive after a year of regular, unprotected intercourse or the inability to carry a pregnancy to term. The rise in infertility rates globally is leading to greater demand for fertility treatments, particularly ovulation induction with human chorionic gonadotropin (hCG) such as Novarel, as women seek solutions to address ovulation issues. Novarel helps treat infertility by stimulating ovulation in women who struggle to release eggs and by supporting sperm production in men with low testosterone levels, thus improving the chances of conception. For example, in July 2024, the Human Fertilisation and Embryology Authority reported a slight increase of 0.4% in the total number of IVF cycles, rising from 82,450 in 2021 to 82,749 in 2022, indicating a recovery from pandemic-related disruptions. This rising prevalence of infertility is driving the demand for Novarel.

The growth of the novarel market is also fueled by increasing healthcare spending. This trend is driven by factors such as the growing prevalence of chronic diseases, an aging population, and advancements in medical technologies. Rising healthcare spending enhances access to effective infertility treatments, including the use of hCG to stimulate ovulation and improve fertility outcomes, resulting in more targeted care in reproductive medicine. For instance, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, compared to a 3.2% increase in 2021. This increase in healthcare spending is contributing to the growth of the novarel market.

The increasing number of drug approvals is also expected to support the growth of the novarel market. Drug approvals refer to the process through which regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) review and authorize new medications for sale and use. The rising number of drug approvals is driven by technological advancements, more investment in healthcare, streamlined regulatory processes, and the expansion of treatments for rare diseases. Approvals for Novarel confirm its safety and efficacy in treating infertility, ensuring its continued availability for clinical use. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in industry-sponsored clinical trials initiated in the UK, from 394 in 2021 to 411 in 2022. This rise in drug approvals is supporting the growth of the novarel market.

The key company operating in the novarel market is Ferring Pharmaceuticals Inc.

North America was the largest region in the novarel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in novarel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the novarel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Novarel is a brand of medication containing human chorionic gonadotropin (hCG), commonly used in fertility treatments. hCG is a hormone essential for the reproductive system, particularly in regulating ovulation in women and testosterone production in men. Administered via injection, its use is closely monitored by healthcare professionals to ensure efficacy and minimize side effects.

Novarel is primarily indicated for inducing ovulation, treating hypogonadotropic hypogonadism, and preserving fertility. Ovulation induction involves using hormonal therapy to stimulate the development and release of eggs. It is distributed through hospitals, pharmacies, and online platforms, serving various end users, including adults and geriatrics.

The novarel market research report is one of a series of new reports that provides novarel market statistics, including novarel industry global market size, regional shares, competitors with a novarel market share, detailed novarel market segments, market trends and opportunities, and any further data you may need to thrive in the novarel industry. This novarel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The novarel market consists of sales of novarel (HCG) injection, novarel pre-filled kits, customized dosage forms, and supportive accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.